Nithin Stephen started his career as a pharmacist who never wanted to stand behind a counter. That instinct led him into the world of CDMOs, where he has spent nearly a decade moving from R&D scientist to project manager to commercial strategy lead — each step deliberately uncomfortable, each one expanding his view of what it takes to build and run a successful drug product manufacturing business. In this episode, Nithin shares how his pharmacist background gave him a rare perspective in the CDMO world and how that cross-functional lens has shaped the way he thinks about client partnerships, capability investment, and commercial growth.
Now serving as commercial strategy lead for drug product, device assembly, and packaging at Resilience, Nithin talks through what clients actually want from a CDMO partner today — and why the answer increasingly comes down to convenience and consolidation. He unpacks the growing demand for fill-finish and device assembly under one roof, what it takes to build credible capability in both, and how CDMOs that get ahead of emerging modality trends — ADCs, oligonucleotides, proprietary device platforms — will separate themselves from those offering only vanilla services. It is an honest, grounded conversation about the business of contract manufacturing from someone who has lived it across multiple organisations and both sides of the client relationship.
Key takeaways:
Clients increasingly want fill-finish, device assembly, and packaging consolidated under one CDMO — the convenience of a single account manager, a single site visit, and a single point of accountability is a genuine competitive differentiator
First impressions matter in CDMO selection — facility cleanliness, equipment quality, people approachability, and quality culture are all signals clients read before a technical conversation begins
CDMOs that capture 50–70% of the most common device platforms while remaining open to proprietary and novel platforms will be better positioned to serve the broadest client base
GLP-1 demand has absorbed significant capacity across the industry, but diversification into ADCs, oligonucleotides, and other emerging modalities is where the next wave of competitive advantage will be built
Pharma companies will always need CDMOs for capabilities and capacity they cannot justify building in-house — but the winning CDMOs will be those who anticipate forthcoming needs two to three years out, not just respond to current demand
Career growth in the CDMO world requires deliberate discomfort — staying comfortable behind a bench, within a familiar organisation, or within a familiar geography limits development
Soft skills, network maintenance, and not burning bridges are as important to long-term career success as technical expertise
Connect with Nithin Stephen, Pharm.D on LinkedIn: https://www.linkedin.com/in/nithin-stephen/
Visit Resilience: https://resilience.com/
Subscribe to Navigating the Combination for more conversations on CDMO strategy, drug product development, and the business of bringing complex medicines to market.
I hope you enjoy this episode! Give it a like, share, and subscribe to not miss the content coming your way weekly.
– Parth & Jonathan and the Navigating the Combination podcast team
Connect with Parth Kothari on LinkedIn: https://www.linkedin.com/in/parthjkothari/ Connect with Jonathan Amaya-Hodges on LinkedIn: https://www.linkedin.com/in/jonathanwhodges/ Visit the Suttons Creek website here: https://suttonscreek.com
Listen to Navigating the Combination on these podcast platforms:
Spotify: https://open.spotify.com/show/033HRTwEj7aFLx9K8ZEsVG
Apple Podcasts: https://podcasts.apple.com/us/podcast/navigating-the-combination/id6786238670
Amazon Podcasts: https://music.amazon.com/podcasts/12169e2d-2323-41db-bdb4-8a8e7841c799
#navigatingthecombination #suttonscreek #combinationproducts #drugdelivery #pharmaconsulting #regulatoryaffairs #medicaldevices #biotech #pharmabiotech #fdaregulation #drugdevicedevelopment #lifesciences #combinationproductdevelopment #pharmapodcast #devicestrategy
Navigating the Combination is the podcast for pharmaceutical and biotech professionals tackling one of the industry's most complex challenges: bringing drug-device combination products to market. Hosted by Parth Kothari and Jonathan Amaya-Hodges of Suttons Creek - the device team for pharma - each episode draws on 650+ combined years of experience and 120+ successful launches to cut through the complexity of combination product development, from device selection and regulatory strategy to OEM alignment, quality systems, and FDA submissions.
Whether you're a VP of Regulatory Affairs weighing your submission strategy, a program director managing a complex OEM relationship, or an executive trying to protect a multi-million-dollar drug investment, this podcast gives you the insight, clarity, and confidence to make the right calls - right the first time.
